BRIEF-Moderna Announces Phase 3 Study Of Investigational Cytomegalovirus (Cmv) Vaccine Did Not Meet Primary Efficacy Endpoint

Oct 22 (Reuters) - Moderna Inc MRNA.O:

• MODERNA ANNOUNCES PHASE 3 STUDY OF INVESTIGATIONAL CYTOMEGALOVIRUS (CMV) VACCINE DID NOT MEET PRIMARY EFFICACY ENDPOINT

• MODERNA - TO DISCONTINUE DEVELOPMENT OF MRNA-1647 IN CONGENITAL CMV

• MODERNA: WILL CONTINUE TO EVALUATE MRNA-1647 IN ONGOING PHASE 2 TRIAL IN BONE MARROW TRANSPLANT PATIENTS

• MODERNA - DOES NOT ANTICIPATE ANY IMPACT TO ITS 2025 FINANCIAL GUIDANCE OR ITS EXPECTATION OF ACHIEVING BREAKEVEN IN 2028

Source text: [ID:]

Further company coverage: MRNA.O

((Reuters.Briefs@thomsonreuters.com;))